Cancer Chemotherapy and Pharmacology, 87, 269-276 Cancer Chemotherapy and Pharmacology, 87, 2, pp. 269-276 Cancer Chemotherapy and Pharmacology, 87(2), 269-276. SPRINGER
Lung cancer: journal of the International Association for the Study of Lung Cancer Lung Cancer, 138, pp. 13-18 Lung Cancer, 138, 13-18 Lung Cancer Lung Cancer, 138, 13-18. ELSEVIER IRELAND LTD Thunnissen, E, Lissenberg-Witte, B I, van den Heuvel, M M, Monkhorst, K, Skov, B G, Sørensen, J B, Mellemgaard, A, Dingemans, A M C, Speel, E J M, de Langen, A J, Hashemi, S M S, Bahce, I, van der Drift, M A, Looijen-Salamon, M G, Gosney, J, Postmus, P E, Samii, S M S, Duplaquet, F, Weynand, B, Durando, X, Penault-Llorca, F, Finn, S, Grady, A O, Oz, B, Akyurek, N, Buettner, R, Wolf, J, Bubendorf, L, Duin, S, Marondel, I, Heukamp, L C, Timens, W, Schuuring, E M D, Pauwels, P & Smit, E F 2019, ' ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib ', Lung Cancer, vol. 138, pp. 13-18 . https://doi.org/10.1016/j.lungcan.2019.09.023 Lung Cancer, 138, 13-18. Elsevier Ireland Ltd Lung cancer, Vol. 138, p. 13-18 (2019)
Annals of Oncology Annals of Oncology, Elsevier, 2019, 30 (8), pp.1321-1328. ⟨10.1093/annonc/mdz167⟩ Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 8 Annals of Oncology, 30, 8, pp. 1321-1328 r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname Annals of Oncology, 30, 1321-1328 Annals of Oncology, 2019, 30 (8), pp.1321-1328. ⟨10.1093/annonc/mdz167⟩ Translational Cancer Research
Annals of oncology, 32(10), 1212-1215. Oxford University Press Annals of Oncology, 32, 10, pp. 1212-1215 Annals of Oncology, 32(10), 1212-1215. Elsevier Ltd. Annals of Oncology, 32, 1212-1215